Genetic markers for breast cancer refer to inherited (germline) or acquired (somatic) changes in DNA that influence a person’s risk of developing breast cancer, the biology of tumors, or how cancers respond to therapy. Understanding these markers helps clinicians estimate risk, guide screening and prevention, choose targeted therapies, and inform family members. Below is a practical, evidence-based overview of the most important genetic markers, what they mean, how they’re tested, and current limitations and future directions.
1) Two big categories: germline vs somatic markers
-
Germline mutations are inherited and present in every cell. They increase lifetime cancer risk and can be passed to children (e.g., BRCA1/2, PALB2, TP53). Testing uses blood or saliva. (NCBI)
-
Somatic mutations occur only in tumor cells and guide treatment choices (e.g., PIK3CA, ERBB2/HER2 amplifications). Tumor sequencing (from biopsy or surgical specimen) identifies these. Somatic markers usually do not indicate inherited risk.
2) High-penetrance (strong) hereditary breast-cancer genes
These genes, when carrying pathogenic variants, typically confer a high lifetime risk of breast cancer (often >30–50% depending on gene and variant). Key examples:
-
BRCA1 and BRCA2 — the best-known hereditary breast and ovarian cancer genes. Pathogenic variants greatly increase lifetime risks of breast and ovarian cancer (and for BRCA2, also prostate and pancreatic cancer). Knowledge of a BRCA pathogenic variant affects screening, risk-reducing surgery options, and targeted therapy (e.g., PARP inhibitors). (NCBI)
-
TP53 (Li-Fraumeni syndrome) — associated with very high risk of multiple early-onset cancers including breast cancer.
-
PTEN (Cowden syndrome), CDH1 (hereditary diffuse gastric cancer with lobular breast cancer risk), STK11 (Peutz-Jeghers), and PALB2 — also considered high-risk genes in many clinical guidelines.
(Clinical risk estimates vary by gene, specific variant, family history, and other factors.) (PubMed)
3) Moderate-risk and other susceptibility genes
These typically confer a smaller but still meaningful increase in risk (e.g., relative risks that are elevated but not as high as BRCA1/2):
-
CHEK2 — associated with a moderate increase in female breast cancer risk and is an established cancer-predisposition gene; some CHEK2 variants are recurrent in particular populations. (NCBI)
-
ATM, BARD1, BRIP1, RAD51C/D, NBN, PALB2 (some classify PALB2 as high risk depending on studies), and others.
-
These genes influence screening recommendations for carriers and, in some cases, treatment choices.
4) Somatic/tumor genetic markers that affect treatment
For people already diagnosed with breast cancer, tumor testing identifies actionable somatic changes:
-
ERBB2/HER2 amplification — determines eligibility for HER2-targeted therapies.
-
PIK3CA mutations — can inform use of PI3K inhibitors in HR+/HER2− metastatic disease.
-
BRCA1/2 (tumor or germline) — tumors with BRCA-pathway defects may respond to PARP inhibitors.
Tumor sequencing panels and immunohistochemistry remain standard ways to find these markers. (PMC)
5) Polygenic risk scores (PRS) — many small markers combined
-
PRS combine hundreds or thousands of common single-nucleotide polymorphisms (SNPs) each with small effects into a single score that estimates inherited risk. PRS can stratify population risk and may eventually refine screening recommendations when combined with family history and single-gene testing. Research is active but clinical implementation and equity (ancestry differences) remain challenges. (PMC)
6) How are genetic markers tested?
-
Single-gene testing — used when a specific syndrome is suspected (e.g., BRCA founder mutation testing).
-
Multi-gene hereditary cancer panels — currently common; they test many germline genes at once (BRCA1/2 plus moderate-risk genes). Panels detect both pathogenic variants and variants of uncertain significance (VUS). (PubMed)
-
Tumor (somatic) sequencing — identifies mutations that can guide therapy.
-
PRS require genotyping arrays or sequencing plus an established algorithm.
Important: Genetic testing should be paired with genetic counseling to explain results, medical implications, cascade testing for relatives, and psychological aspects.
7) Clinical implications of finding a pathogenic variant
-
For unaffected carriers: increased surveillance (earlier and/or more frequent mammography/MRI), risk-reducing options (e.g., prophylactic mastectomy or oophorectomy for BRCA carriers), and lifestyle or chemoprevention options may be discussed. Guidelines (e.g., NCCN) provide testing criteria and management pathways. (PubMed)
-
For people with cancer: germline or somatic results can affect systemic therapy choices (e.g., PARP inhibitors for BRCA-deficient tumors) and surgical decisions. (PMC)
8) Limitations, uncertainties, and pitfalls
-
Variants of uncertain significance (VUS): common in multi-gene tests. VUS should not be used to guide major clinical decisions.
-
Ancestry gaps: Most PRS and some variant databases were developed in European ancestry cohorts; accuracy can vary by ancestry. (PMC)
-
Not all familial breast cancer is explained by known genes: Many families with strong histories have no identifiable pathogenic variant; environment and non-genetic factors also matter.
-
Psychological, insurance, and reproductive implications: learning one’s genetic status can have emotional and familial consequences—genetic counseling is essential.
9) Emerging directions
-
Better integration of PRS with single-gene testing and family history to personalize screening and prevention. (PMC)
-
Expanded population screening debates: some experts propose broader BRCA screening in certain populations or age groups; others recommend targeted approaches guided by family history and risk. (NCBI)
-
Improved therapies targeting DNA-repair defects and individualized treatment based on tumor genomics.
10) Practical takeaways
-
BRCA1/2 remain the most clinically actionable germline markers for hereditary breast and ovarian cancer; testing affects screening, prevention, and therapy choices. (NCBI)
-
Several other genes (PALB2, TP53, PTEN, CHEK2, ATM, etc.) also raise risk and are included on modern panels; management differs by gene and variant. (PMC)
-
Tumor sequencing identifies somatic markers that guide targeted therapy (HER2, PIK3CA, BRCA pathway defects). (PMC)
-
PRS are promising but not yet a universal substitute for family-history–based genetic counseling; they will likely be an additional tool to personalize risk. (PMC)
Post a Comment